National Institute for Health and Care Excellence (NICE) have published their final draft guidance today recommending the following COVID-19 treatments: Paxlovid, Xevudy (also called Sotrovimab), RoActerma. We are pleased that the final draft guidance has made available a treatment which can be taken by kidney patients.

To read more on the NICE final draft guidance please visit: